https://www.selleckchem.com/pr....oducts/imidazole-ket
4 ± 0.6 vs. 2.1 ± 0.5, p=.00 and lower occurrence of new-onset atrial fibrillation (AF) (7.8% vs. 20.4%, p=.048). Multivariate analysis demonstrated that resting LVOT gradient at the last clinical check-up was an independent predictor of all-cause mortality (HR=1.021, 95%CI 1.002-1.040, p=.027). This registry suggests that mildly symptomatic patients with HOCM treated with ASA have comparable survival to that of medically treated patients, with the improvement of NYHA class and lower occurrence of new-onset AF. All-ca
Like
Comment
Share
